Drug Profile
Research programme: IL-2 inducible T-cell kinase inhibitors - Aclaris Therapeutics
Latest Information Update: 10 May 2019
Price :
$50
*
At a glance
- Originator Confluence Life Sciences
- Developer Aclaris Therapeutics
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cutaneous T-cell lymphoma; Inflammation; Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 10 May 2019 Discontinued for Cutaneous T-cell lymphoma in USA (PO)
- 10 May 2019 Discontinued for Inflammation in USA (PO)
- 10 May 2019 Discontinued for Precursor T-cell lymphoblastic leukaemia-lymphoma in USA (PO)